Loading...

Neuren Pharmaceuticals

ASX:NEU
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NEU
ASX
A$138M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury. The last earnings update was 84 days ago. More info.


Add to Portfolio Compare Print
  • Neuren Pharmaceuticals has significant price volatility in the past 3 months.
NEU Share Price and Events
7 Day Returns
-2.1%
ASX:NEU
-6.8%
AU Pharmaceuticals
-0.9%
AU Market
1 Year Returns
-49.6%
ASX:NEU
-29.3%
AU Pharmaceuticals
4.2%
AU Market
NEU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Neuren Pharmaceuticals (NEU) -2.1% 21.1% 22.1% -49.6% 23.2% -31%
AU Pharmaceuticals -6.8% 9.7% 0.4% -29.3% -48.9% -30.6%
AU Market -0.9% 1.4% 6% 4.2% 19% 11%
1 Year Return vs Industry and Market
  • NEU underperformed the Pharmaceuticals industry which returned -29.3% over the past year.
  • NEU underperformed the Market in Australia which returned 4.2% over the past year.
Price Volatility
NEU
Industry
5yr Volatility vs Market

NEU Value

 Is Neuren Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Neuren Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Neuren Pharmaceuticals.

ASX:NEU Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:NEU
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 30%) (0%))
0.82
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.82 * 5.96%)
7.2%

Discounted Cash Flow Calculation for ASX:NEU using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Neuren Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:NEU DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 7.2%)
2020 -4.70 Analyst x1 -4.38
2021 0.50 Analyst x1 0.44
2022 0.46 Est @ -8.93% 0.37
2023 0.43 Est @ -5.56% 0.33
2024 0.42 Est @ -3.2% 0.29
2025 0.41 Est @ -1.55% 0.27
2026 0.41 Est @ -0.39% 0.25
2027 0.41 Est @ 0.42% 0.24
2028 0.41 Est @ 0.99% 0.22
2029 0.42 Est @ 1.39% 0.21
Present value of next 10 years cash flows A$-1.77
ASX:NEU DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= A$0.42 × (1 + 2.31%) ÷ (7.2% – 2.31%)
A$8.78
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$8.78 ÷ (1 + 7.2%)10
A$4.38
ASX:NEU Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$-1.77 + A$4.38
A$2.61
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$2.61 / 100.17
A$0.03
ASX:NEU Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$0.03
Current discount Discount to share price of A$1.38
= -1 x (A$1.38 - A$0.03) / A$0.03
-5197.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Neuren Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Neuren Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Neuren Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:NEU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.03
ASX:NEU Share Price ** ASX (2019-07-18) in AUD A$1.38
Australia Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 20.6x
Australia Market PE Ratio Median Figure of 546 Publicly-Listed Companies 16.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Neuren Pharmaceuticals.

ASX:NEU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:NEU Share Price ÷ EPS (both in AUD)

= 1.38 ÷ 0.03

44.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neuren Pharmaceuticals is overvalued based on earnings compared to the AU Pharmaceuticals industry average.
  • Neuren Pharmaceuticals is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does Neuren Pharmaceuticals's expected growth come at a high price?
Raw Data
ASX:NEU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 44.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
1.5%per year
Global Pharmaceuticals Industry PEG Ratio Median Figure of 116 Publicly-Listed Pharmaceuticals Companies 1.51x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

ASX:NEU PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 44.48x ÷ 1.5%

29.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neuren Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Neuren Pharmaceuticals's assets?
Raw Data
ASX:NEU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.25
ASX:NEU Share Price * ASX (2019-07-18) in AUD A$1.38
Australia Pharmaceuticals Industry PB Ratio Median Figure of 27 Publicly-Listed Pharmaceuticals Companies 3.6x
Australia Market PB Ratio Median Figure of 1,693 Publicly-Listed Companies 1.7x
ASX:NEU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:NEU Share Price ÷ Book Value per Share (both in AUD)

= 1.38 ÷ 0.25

5.6x

* Primary Listing of Neuren Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neuren Pharmaceuticals is overvalued based on assets compared to the AU Pharmaceuticals industry average.
X
Value checks
We assess Neuren Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Neuren Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NEU Future Performance

 How is Neuren Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Neuren Pharmaceuticals expected to grow at an attractive rate?
  • Neuren Pharmaceuticals's earnings growth is positive but not above the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Neuren Pharmaceuticals's earnings growth is positive but not above the Australia market average.
  • Neuren Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:NEU Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:NEU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 1.5%
ASX:NEU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -47.7%
Australia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 55%
Australia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 32.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7.4%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:NEU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:NEU Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 6 1 1 1
2020-12-31 0 -5 -5 1
2019-12-31 0 -14 -13 1
ASX:NEU Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 14 6 3
2018-09-30 7 0 3
2018-06-30 1 -6 3
2018-03-31 1 -6 3
2017-12-31 1 -6 3
2017-09-30 2 -7 -2
2017-06-30 3 -8 -8
2017-03-31 3 -10 -10
2016-12-31 3 -12 -12
2016-09-30 2 -14 -14
2016-06-30 0 -17 -15
2016-03-31 1 -15 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Neuren Pharmaceuticals's earnings are expected to grow by 1.5% yearly, however this is not considered high growth (20% yearly).
  • Neuren Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:NEU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Neuren Pharmaceuticals Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NEU Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.01 0.01 0.01 1.00
2020-12-31 -0.05 -0.05 -0.05 1.00
2019-12-31 -0.13 -0.13 -0.13 1.00
ASX:NEU Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.03
2018-09-30 0.03
2018-06-30 0.03
2018-03-31 0.03
2017-12-31 0.04
2017-09-30 -0.03
2017-06-30 -0.10
2017-03-31 -0.12
2016-12-31 -0.14
2016-09-30 -0.16
2016-06-30 -0.18
2016-03-31 -0.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Neuren Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Neuren Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Neuren Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NEU Past Performance

  How has Neuren Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Neuren Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Neuren Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Neuren Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Neuren Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the Global Pharmaceuticals industry average.
Earnings and Revenue History
Neuren Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Neuren Pharmaceuticals Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NEU Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 13.99 3.07 2.07
2018-09-30 7.31 2.91 1.75
2018-06-30 0.63 2.74 1.43
2018-03-31 0.63 3.02 1.50
2017-12-31 0.63 3.29 1.57
2017-09-30 1.81 -2.45 1.58
2017-06-30 2.99 -8.19 1.59
2017-03-31 3.07 -10.10 1.72
2016-12-31 3.15 -12.01 1.84
2016-09-30 1.69 -13.72 2.49
2016-06-30 0.22 -15.43 3.14
2016-03-31 0.95 -14.41 3.13
2015-12-31 1.67 -13.40 3.12
2015-09-30 2.40 -11.19 2.94
2015-06-30 3.12 -8.99 2.77
2015-03-31 3.02 -8.64 2.70
2014-12-31 2.93 -8.30 2.64
2014-09-30 3.20 -10.16 2.46
2014-06-30 3.47 -12.03 2.28
2014-03-31 4.13 -11.23 2.32
2013-12-31 4.79 -10.44 2.36
2013-09-30 5.20 -8.67 2.85
2013-06-30 4.99 -5.96 2.62
2013-03-31 4.58 -5.49 2.60
2012-12-31 4.24 -5.11 2.60
2012-09-30 3.75 -5.63 3.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Neuren Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Neuren Pharmaceuticals used its assets more efficiently than the AU Pharmaceuticals industry average last year based on Return on Assets.
  • Neuren Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Neuren Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Neuren Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NEU Health

 How is Neuren Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Neuren Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Neuren Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Neuren Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Neuren Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Neuren Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Neuren Pharmaceuticals Company Filings, last reported 6 months ago.

ASX:NEU Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 24.67 0.00 23.58
2018-09-30 24.67 0.00 23.58
2018-06-30 17.52 0.00 11.41
2018-03-31 17.52 0.00 11.41
2017-12-31 16.36 0.00 4.71
2017-09-30 16.36 0.00 4.71
2017-06-30 0.98 0.00 1.27
2017-03-31 0.98 0.00 1.27
2016-12-31 4.18 0.00 5.05
2016-09-30 4.18 0.00 5.05
2016-06-30 7.58 0.00 8.13
2016-03-31 7.58 0.00 8.13
2015-12-31 14.40 0.00 16.64
2015-09-30 14.40 0.00 16.64
2015-06-30 15.34 0.00 17.65
2015-03-31 15.34 0.00 17.65
2014-12-31 19.08 0.00 20.82
2014-09-30 19.08 0.00 20.82
2014-06-30 21.22 0.00 22.47
2014-03-31 21.22 0.00 22.47
2013-12-31 24.40 0.00 24.38
2013-09-30 23.60 0.00 23.58
2013-06-30 4.69 0.00 3.45
2013-03-31 4.46 0.00 3.28
2012-12-31 6.36 0.00 5.15
2012-09-30 6.38 0.00 5.17
  • Neuren Pharmaceuticals has no debt.
  • Neuren Pharmaceuticals has not taken on any debt in the past 5 years.
  • Neuren Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
  • Neuren Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Neuren Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Neuren Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NEU Dividends

 What is Neuren Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Neuren Pharmaceuticals dividends.
If you bought A$2,000 of Neuren Pharmaceuticals shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Neuren Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Neuren Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:NEU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 146 Stocks 2.9%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4.1%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:NEU Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Neuren Pharmaceuticals has not reported any payouts.
  • Unable to verify if Neuren Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Neuren Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Neuren Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Neuren Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Neuren Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Neuren Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NEU Management

 What is the CEO of Neuren Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Neuren Pharmaceuticals has no CEO, or we have no data on them.
Management Team

Richard Treagus

TITLE
Executive Chairman

Larry Glass

TITLE
Chief Science Officer
TENURE
15.5 yrs

Jon Pilcher

TITLE
CFO & Company Secretary
TENURE
5.9 yrs
Board of Directors Tenure

Average tenure of the Neuren Pharmaceuticals board of directors in years:

1
Average Tenure
  • The average tenure for the Neuren Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Richard Treagus

TITLE
Executive Chairman
TENURE
6.5 yrs

Trevor Scott

TITLE
Independent Non-Executive Director
TENURE
17.3 yrs

Dianne Angus

TITLE
Independent Non-Executive Director
AGE
59
TENURE
1 yrs

Patrick Davies

TITLE
Independent Non-Executive Director
TENURE
1 yrs

Jenny Harry

TITLE
Independent Non-Executive Director
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
30. Dec 18 Sell Lanstead Capital Limited Partnership Company 27. Dec 18 27. Dec 18 -4,164,223 A$1.40 A$-5,829,912
30. Dec 18 Buy Lanstead Capital Limited Partnership Company 03. Sep 18 03. Sep 18 165,641 A$1.34 A$221,296
30. Dec 18 Sell Lanstead Capital Limited Partnership Company 17. May 18 11. Dec 18 -7,645 A$3.27 A$-21,073
30. Sep 18 Buy Richard Treagus Individual 28. Sep 18 28. Sep 18 16,000 A$1.24 A$19,840
15. Aug 18 Buy Jenny Harry Individual 10. Aug 18 10. Aug 18 14,084 A$1.46 A$20,584
15. Aug 18 Buy Patrick Davies Individual 10. Aug 18 14. Aug 18 69,646 A$1.44 A$100,001
X
Management checks
We assess Neuren Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Neuren Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NEU News

Simply Wall St News

Do Institutions Own Neuren Pharmaceuticals Limited (ASX:NEU) Shares?

Check out our latest analysis for Neuren Pharmaceuticals ASX:NEU Ownership Summary, June 14th 2019 What Does The Institutional Ownership Tell Us About Neuren Pharmaceuticals? … Less than 5% of Neuren Pharmaceuticals is held by institutional investors. … Insider Ownership Of Neuren Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Have Insiders Been Buying Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

That means that even when the share price was higher than AU$1.15 (the recent price), an insider wanted to purchase shares … In our view, the price an insider pays for shares is very important … As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

Simply Wall St -

Should You Be Excited About Neuren Pharmaceuticals Limited's (ASX:NEU) 12% Return On Equity?

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Neuren Pharmaceuticals Limited (ASX:NEU). … One way to conceptualize this, is that for each A$1 of shareholders' equity it has, the company made A$0.12 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Imagine Owning Neuren Pharmaceuticals (ASX:NEU) While The Price Tanked 62%

In that relatively short period, the share price has plunged 62%. … Even if you look out three years, the returns are still disappointing, with the share price down (the share price is down 49%) in that time. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Simply Wall St -

Neuren Pharmaceuticals Limited (ASX:NEU): Time For A Financial Health Check

The direct benefit for Neuren Pharmaceuticals Limited (ASX:NEU), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

What Type Of Shareholder Owns Neuren Pharmaceuticals Limited's (ASX:NEU)?

Every investor in Neuren Pharmaceuticals Limited (ASX:NEU) should be aware of the most powerful shareholder groups. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Neuren Pharmaceuticals is a smaller company with a market capitalization of AU$159m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Neuren Pharmaceuticals Limited (ASX:NEU) Delivered A Better ROE Than Its Industry

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … To keep the lesson grounded in practicality, we'll use ROE to better understand Neuren Pharmaceuticals Limited (ASX:NEU). … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is Neuren Pharmaceuticals Limited's (ASX:NEU) Balance Sheet A Threat To Its Future?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is NEU right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Does Neuren Pharmaceuticals Limited's (ASX:NEU) PE Ratio Warrant A Sell?

and want to begin learning the link between Neuren Pharmaceuticals Limited (ASX:NEU)’s fundamentals and stock market performance. … Neuren Pharmaceuticals Limited (ASX:NEU) is currently trading at a trailing P/E of 75.2x, which is higher than the industry average of 22.6x. … While this makes NEU appear like a stock to avoid or sell if you own it, you might change your mind after I explain the assumptions behind the P/E ratio

Simply Wall St -

Neuren Pharmaceuticals Limited (ASX:NEU): How Does It Impact Your Portfolio?

Neuren Pharmaceuticals's beta of 0.35 indicates that the stock value will be less variable compared to the whole stock market. … Based on this beta value, NEU appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … Therefore, investors can expect a high beta associated with the size of NEU, but a lower beta given the nature of the industry it operates in.

Simply Wall St -

NEU Company Info

Description

Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury. Its lead product is trofinetide, which has completed Phase II clinical trials for the treatment of Rett syndrome; is in Phase II clinical trials for the treatment of Fragile X syndrome; and conducted Phase II clinical trials for the treatment moderate to severe traumatic brain injury. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid syndrome. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.

Details
Name: Neuren Pharmaceuticals Limited
NEU
Exchange: ASX
Founded: 1993
A$138,232,409
100,168,413
Website: http://www.neurenpharma.com
Address: Neuren Pharmaceuticals Limited
697 Burke Road,
Suite 201,
Camberwell,
Victoria, 3124,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX NEU Ordinary Shares Australian Securities Exchange AU AUD 03. Feb 2005
OTCPK NURP.F Ordinary Shares Pink Sheets LLC US USD 03. Feb 2005
CHIA NEU Ordinary Shares Chi-X Australia AU AUD 03. Feb 2005
Number of employees
Current staff
Staff numbers
8
Neuren Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 10:31
End of day share price update: 2019/07/18 00:00
Last estimates confirmation: 2019/03/11
Last earnings filing: 2019/04/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.